Drugs / AC-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07070674 | Jul 2024 → Sep 2026 overdue | acute graft versus host disease | Accro Bioscience (Suzhou) Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AC-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07070674 ↗ |
| Route | Oral | “administered orally” NCT07070674 ↗ |